{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:10:28Z","timestamp":1787008228417,"version":"build-2736575974"},"reference-count":16,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Psychedelic Medicine"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Bipolar II disorder (BD-II) is often associated with chronic and treatment resistant major depressive episodes. Psilocybin has shown promise for its rapid-acting antidepressant effects, though its impact on bipolar depression remains unexplored. In the present subgroup analysis of an already published trial on treatment-resistant depression (TRD), we aimed to preliminarily\u00a0evaluate the safety and efficacy of psilocybin in patients with BD-II.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Adults with TRD associated with BD-II, excluding those with psychosis were included. Participants underwent one or two psilocybin sessions, each with a dose of 25 mg, along with preparatory and integrative psychotherapy sessions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of four participants with a mean age of 37.5\u2009 \u00b1 \u20094.15 years were included. At baseline, the mean Montgomery\u2013\u00c5sberg Depression Rating Scale (MADRS) score was 32.5 (95% CI: 26.3\u201338.7, SD = 3.87). By week 2 post-dose, mean MADRS decreased to 20.3, and 2 weeks after dose 2, it further dropped to 19. At the end of the 6-month study, the mean MADRS score was 21.3. Young Mania Rating Scale scores remained stable at a mean of one throughout the study with no evidence of treatment emergent mania, hypomania or psychosis observed in any participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These findings suggest potential improvement in depressive symptoms with psilocybin administration in BD-II. Future studies with larger sample size are required to replicate our results and further evaluate antidepressant effects of psilocybin in bipolar depression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/psymed.2024.0032","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T04:33:52Z","timestamp":1731904432000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder"],"prefix":"10.1177","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7010-1785","authenticated-orcid":false,"given":"Shakila","family":"Meshkat","sequence":"first","affiliation":[{"name":"University of Toronto, Toronto, Canada."},{"name":"Braxia Health, Canadian Rapid Treatment Centre of Excellence (CRTCE), Braxia Scientific, Mississauga, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Kaczmarek","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Canada."},{"name":"Braxia Health, Canadian Rapid Treatment Centre of Excellence (CRTCE), Braxia Scientific, Mississauga, Canada."},{"name":"Department of Pharmacology &amp; Toxicology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Doyle","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Canada."},{"name":"Braxia Health, Canadian Rapid Treatment Centre of Excellence (CRTCE), Braxia Scientific, Mississauga, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Brudner","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Canada."},{"name":"Braxia Health, Canadian Rapid Treatment Centre of Excellence (CRTCE), Braxia Scientific, Mississauga, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano A.","family":"Gomes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Blainey","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geneva","family":"Weiglein","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Canada."},{"name":"Braxia Health, Canadian Rapid Treatment Centre of Excellence (CRTCE), Braxia Scientific, Mississauga, Canada."},{"name":"Department of Pharmacology &amp; Toxicology, University of Toronto, Toronto, Canada."},{"name":"Department of Psychiatry, University of Toronto, Toronto, Canada."},{"name":"Brain and Cognition Discovery Foundation, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Canada."},{"name":"Department of Psychiatry, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Canada."},{"name":"Braxia Health, Canadian Rapid Treatment Centre of Excellence (CRTCE), Braxia Scientific, Mississauga, Canada."},{"name":"Department of Pharmacology &amp; Toxicology, University of Toronto, Toronto, Canada."},{"name":"Department of Psychiatry, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20997"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31544-0"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2022.12.012"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S273503"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.01.024"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.01.142"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2017.1320734"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112749"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.03.165"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2024.05.051"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115531"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.4685"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.01.005"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279073"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221131997"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1221131"}],"container-title":["Psychedelic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/psymed.2024.0032","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/psymed.2024.0032","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/psymed.2024.0032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:27:30Z","timestamp":1777685250000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/psymed.2024.0032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1089\/psymed.2024.0032"],"URL":"https:\/\/doi.org\/10.1089\/psymed.2024.0032","relation":{},"ISSN":["2831-4425","2831-4433"],"issn-type":[{"value":"2831-4425","type":"print"},{"value":"2831-4433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}